Factors associated with CIN2-3 recurrence: A single center retrospective analysis.

IF 4.1 4区 医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Human Vaccines & Immunotherapeutics Pub Date : 2025-12-01 Epub Date: 2025-02-21 DOI:10.1080/21645515.2025.2469410
Zhuo-Yi Li, Kai Wang, Xiao-Ling Shen, Qing Li
{"title":"Factors associated with CIN2-3 recurrence: A single center retrospective analysis.","authors":"Zhuo-Yi Li, Kai Wang, Xiao-Ling Shen, Qing Li","doi":"10.1080/21645515.2025.2469410","DOIUrl":null,"url":null,"abstract":"<p><p>Cervical intraepithelial neoplasia, grade 2-3 (CIN2-3), classified as histologic high-grade squamous intraepithelial lesion (HSIL), is associated with a higher recurrence rate and an increased risk of developing cervical cancer. The predictive and influencing factors for CIN2+ relapse are still uncertain and controversial. This study aims to further clarify the risk factors of CIN 2-3 recurrence. The retrospective cohort study enrolled 142 patients with CIN 2-3, aged between 20 to 60 years, all of whom received treatments to remove the lesions. All patients were followed for at least two years to assess outcomes. The primary outcome indicators were high-risk HPV (HR-HPV) status and cervical lesions status within two years after treatment. Fisher's exact test or Pearson's chi-squared test and the Kruskal-Wallis (K-W/H) test were used for univariate analysis. Logistic regression analysis was applied to identify independent risk factors, and the results were presented using a forest plot. The study found no significant differences in basic characteristics and HR-HPV status, except for parity (<i>p</i> = .020). HPV genotype before treatment and margin status were significantly associated with cervical lesion status after treatment, with P-values of 0.003 and 0.031, respectively. Cytology before treatment and HPV vaccination were independent factors influencing cervical lesions status two years after treatment, with odds ratios (OR) of 0.634 (95% CI: 0.443-0.908) and 0.340 (95% CI: 0.121-0.952), respectively. This study is the first to report independent factors influencing CIN 2-3 recurrence and underscores the importance of considering adjuvant HPV vaccination for women with cervical preinvasive disease.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2469410"},"PeriodicalIF":4.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11849945/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2469410","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cervical intraepithelial neoplasia, grade 2-3 (CIN2-3), classified as histologic high-grade squamous intraepithelial lesion (HSIL), is associated with a higher recurrence rate and an increased risk of developing cervical cancer. The predictive and influencing factors for CIN2+ relapse are still uncertain and controversial. This study aims to further clarify the risk factors of CIN 2-3 recurrence. The retrospective cohort study enrolled 142 patients with CIN 2-3, aged between 20 to 60 years, all of whom received treatments to remove the lesions. All patients were followed for at least two years to assess outcomes. The primary outcome indicators were high-risk HPV (HR-HPV) status and cervical lesions status within two years after treatment. Fisher's exact test or Pearson's chi-squared test and the Kruskal-Wallis (K-W/H) test were used for univariate analysis. Logistic regression analysis was applied to identify independent risk factors, and the results were presented using a forest plot. The study found no significant differences in basic characteristics and HR-HPV status, except for parity (p = .020). HPV genotype before treatment and margin status were significantly associated with cervical lesion status after treatment, with P-values of 0.003 and 0.031, respectively. Cytology before treatment and HPV vaccination were independent factors influencing cervical lesions status two years after treatment, with odds ratios (OR) of 0.634 (95% CI: 0.443-0.908) and 0.340 (95% CI: 0.121-0.952), respectively. This study is the first to report independent factors influencing CIN 2-3 recurrence and underscores the importance of considering adjuvant HPV vaccination for women with cervical preinvasive disease.

与CIN2-3复发相关的因素:单中心回顾性分析。
宫颈上皮内瘤变2-3级(CIN2-3),属于组织学级别高级别鳞状上皮内病变(HSIL),复发率较高,发展为宫颈癌的风险增加。CIN2+复发的预测因素和影响因素仍然不确定和有争议。本研究旨在进一步明确CIN 2-3复发的危险因素。回顾性队列研究纳入142例CIN 2-3患者,年龄在20 - 60岁之间,所有患者均接受了切除病变的治疗。所有患者至少随访两年以评估结果。主要结局指标是治疗后两年内高危HPV (HR-HPV)状态和宫颈病变状态。单因素分析采用Fisher精确检验或Pearson卡方检验和Kruskal-Wallis (K-W/H)检验。采用Logistic回归分析确定独立危险因素,并以森林样地呈现结果。研究发现基本特征和HR-HPV状态没有显著差异,除了胎次(p = 0.020)。治疗前HPV基因型和切缘状态与治疗后宫颈病变状态显著相关,p值分别为0.003和0.031。治疗前细胞学检查和HPV疫苗接种是影响治疗后2年宫颈病变状态的独立因素,比值比(OR)分别为0.634 (95% CI: 0.443-0.908)和0.340 (95% CI: 0.121-0.952)。这项研究首次报道了影响CIN 2-3复发的独立因素,并强调了宫颈浸润前疾病妇女考虑辅助接种HPV疫苗的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
CiteScore
7.90
自引率
8.30%
发文量
489
审稿时长
3-6 weeks
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信